MedPath

Innovent Biologics (Suzhou) Co., Ltd

Innovent Biologics (Suzhou) Co., Ltd logo
🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

166

Active:18
Completed:83

Trial Phases

4 Phases

Phase 1:105
Phase 2:27
Phase 3:31
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (164 trials with phase data)• Click on a phase to view related trials

Phase 1
105 (64.0%)
Phase 3
31 (18.9%)
Phase 2
27 (16.5%)
Not Applicable
1 (0.6%)

A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)

Not Applicable
Not yet recruiting
Conditions
Pancreatic Cancer
Interventions
Drug: Placebo
First Posted Date
2025-07-15
Last Posted Date
2025-07-15
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Target Recruit Count
201
Registration Number
NCT07066098
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases

Not yet recruiting
Conditions
Non-Small Cell Lung Cancer
Interventions
First Posted Date
2025-06-06
Last Posted Date
2025-06-06
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Target Recruit Count
100
Registration Number
NCT07008287

Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity

Phase 1
Recruiting
Conditions
Obesity
Interventions
First Posted Date
2025-06-03
Last Posted Date
2025-07-09
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Target Recruit Count
98
Registration Number
NCT07000955
Locations
🇨🇳

The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China

IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Phase 1
Recruiting
Conditions
Unresectable Locally Advanced or Metastatic Solid Tumors
Interventions
First Posted Date
2025-05-16
Last Posted Date
2025-05-16
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Target Recruit Count
250
Registration Number
NCT06974812
Locations
🇨🇳

Fujian cancer hospital, Fuzhou, Fujian, China

A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Healthy and Asthmatic Participants

Phase 1
Recruiting
Conditions
Asthma
Interventions
Drug: Placebo
First Posted Date
2025-04-27
Last Posted Date
2025-05-28
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Target Recruit Count
60
Registration Number
NCT06947408
Locations
🇨🇳

China-japan Friendship Hosipital, Beijing, Beijing, China

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 33
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.